Skip to main content

Human LRRC32/GARP Alexa Fluor™ Plus 555-conjugated Antibody

R&D Systems, part of Bio-Techne | Catalog # FAB6055AFP555

Catalog #
Availability
Size / Price
Qty
Loading...
FAB6055AFP555-100UG

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, CyTOF-ready

Label

Alexa Fluor Plus 555 (Excitation = 558 nm, Emission = 572 nm)

Antibody Source

Monoclonal Rat IgG2A Clone # 855151

Product Specifications

Specificity

Detects human LRRC32/GARP in ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse LRRC32 is observed.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Applications

Application
Recommended Usage

CyTOF-ready

Optimal dilution of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilution of this antibody should be experimentally determined.

Background: LRRC32/GARP

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant), is an 80 kDa type I transmembrane glycoprotein (1). Mature human LRRC32 consists of a 608 amino acid (aa) extracellular domain (ECD) that contains 22 leucine‑rich repeats, a 21 aa transmembrane segment, and a 14 aa cytoplasmic domain (2, 3). Within the ECD, human LRRC32 shares approximately 80% aa sequence identity with mouse and rat LRRC32. LRRC32 is widely expressed during embryogenesis and on adult platelets (4, 5). Human LRRC32 is identified as a lineage specific key receptor for human T cells. It is selectively expressed on activated FOXP3+ regulatory T cells (Treg) (6‑10). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells (6‑8). LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells (9, 10). The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation (11).

References

  1. Battaglia, M. and M.G. Roncarolo (2009) Eur. J. Immunol. 39:3296.
  2. Ollendorff, V. et al. (1994) Cell Growth Differ. 5:213.
  3. Bella, J. et al. (2008) Cell Mol Life Sci. 65:2307.
  4. Roubin, R. et al. (1996) Int. J. Dev. Biol. 40:545.
  5. Macaulay, I.C. et al. (2007) Blood 109:3260.
  6. Wang, R. et al. (2008) PloS ONE 3:e2705.
  7. Wang, R. et al. (2009) Proc. Natl. Acad. Sci. 106:13439.
  8. Probst-Kepper, M. et al. (2009) J. Cell. Mol. Med. 13:3343.
  9. Tran, D.Q. et al. (2009) Proc. Natl. Acad. Sci. 106:13445.
  10. Stockis, J. et al. (2009) Eur. J. Immunol. 39:3315.
  11. Vignali, D.A. et al. (2008) Nat. Rev. Immunol. 8:523.

Long Name

Leucine-rich Repeat Containing 32/Glycoprotein A Repetitions Predominant

Alternate Names

D11S833E, GARP, Garpin

Entrez Gene IDs

2615 (Human); 434215 (Mouse)

Gene Symbol

LRRC32

UniProt

Additional LRRC32/GARP Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices


This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer, excluding contract research or any fee for service research, and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; or (c) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...